title: Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.
authors.affiliation: Steffen Borrmann is with the Kenya Medical Research Institute, Wellcome Trust Research Programme, Centre for Geographical Medicine Research, Coast, Kilifi, Kenya. sborrmann@kilifi.kemri-wellcome.org
authors.forename: Steffen
authors.initials: S
authors.lastname: Borrmann
authors.forename: Tim
authors.initials: T
authors.lastname: Peto
authors.forename: Robert W
authors.initials: RW
authors.lastname: Snow
authors.forename: Win
authors.initials: W
authors.lastname: Gutteridge
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: White
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000401:mortality / Q000469:parasitology / Q000517:prevention & control; D010963:Plasmodium falciparum / Q000187:drug effects; D055502:Secondary Prevention; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials